<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114137</url>
  </required_header>
  <id_info>
    <org_study_id>002</org_study_id>
    <nct_id>NCT03114137</nct_id>
  </id_info>
  <brief_title>Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose</brief_title>
  <acronym>CADRE</acronym>
  <official_title>Heart, Arteries and Sikle Cell Disease, a Multicentric Cohort of Cardiovascular Complications in Subsaharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiologie et Développement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>laboratory of excellence GR-Ex</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiologie et Développement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CADRE study is a multinational observational cohort of patients with sickle-cell disease
      (SCD) in five west and central sub-Saharan African countries. The aim of this project is to
      describe the incidence and assess the predictive factors of SCD-related micro- and
      macro-vascular complications in sub-Saharan Africa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease (SCD), one of the lost common genetic diseases worldwide, is caused by a
      mutation in the β globin gene. Most patients with this disease are homozygous for the βS
      allele (SS), whereas others have inherited a βS allele with another mutation in the β globin
      gene. In addition to repeated acute ischemic insults due to the red blood cells sickling in
      the microcirculation, a chronic vasculopathy leads to organ injuries, such as kidney disease,
      stroke, pulmonary hypertension, retinopathy, bone infarcts, and leg ulcers.

      CADRE is a multinational prospective observational study undertaken in five countries in
      sub-Saharan Africa. Patients with SCD will be recruited through outpatients' clinics in
      public, university and private hospitals and research centers in five countries. The CADRE
      protocol was approved by the relevant national ethics committee in each of the participating
      countries.

      Primary endpoint is to measure the prevalence and the incidence of the main vascular
      complications in the main types of SCD: glomerulopathy, nephropathy, cardiopathy, pulmonary
      hypertension, retinopathy, strokes, osteonecrosis and leg ulcers.

      Secondary endpoints are:

        -  to define the clinical and biological predictors of SCD vasculopathy in Africa

        -  to search for genetic risk factors for the SCD-related cardiovascular complications, in
           particular alpha thalassemia, persistence of foetal hemoglobin and other candidate
           genetic polymorphisms

        -  to search for functional risk factors (pulse wave velocity, capillary vasodilatation,
           blood visosity) for the SCD-related cardiovascular complications

        -  to search for new biological determinant of SCD-related cardiovascular complications, in
           particular alternative markers of hemolysis (microparticules, free heme) and
           inflammation (cytokines, leucocytes phenotyping, NET (neutrophile extracellular traps))
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: glomerulopathy</measure>
    <time_frame>10 years</time_frame>
    <description>urinary albumin/creatinin ratio (mg/g)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: cardiopathy</measure>
    <time_frame>10 years</time_frame>
    <description>left ventricular ejection fraction &lt; 60 %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: pulmonary hypertension</measure>
    <time_frame>10 years</time_frame>
    <description>tricuspid regurgitation jet velocity (m/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and incidence and the 10 year-incidence of the main SCD-related vascular complications in different phenotypes of SCD: retinopathy</measure>
    <time_frame>10 years</time_frame>
    <description>retinal examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD:stroke</measure>
    <time_frame>10 years</time_frame>
    <description>clinical diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD:osteonecrosis</measure>
    <time_frame>10 years</time_frame>
    <description>standard radiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: leg ulcers</measure>
    <time_frame>10 years</time_frame>
    <description>clinical diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and 10 year-incidence of SCD-related vascular complications in different phenotypes of SCD: priapism</measure>
    <time_frame>10 years</time_frame>
    <description>clinical diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potential biological risk marker measured at baseline and follow up visits: carotid-femoral pulse wave velocity</measure>
    <time_frame>10 years</time_frame>
    <description>measured by Pulsepen, m/s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biological risk marker measured at baseline and follow up visits: complete blood count</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biological risk marker measured at baseline and follow up visits: LDH level</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biological risk marker measured at baseline and follow up visits: bilirubin level</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biological risk marker measured at baseline and follow up visits: microparticules measure</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biological risk marker measured at baseline and follow up visits: free heme level</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biological risk marker measured at baseline and follow up visits: inflammatory cytokines</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential biological risk marker measured at baseline and follow up visits: neutrophil extracellular traps</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>sickle cell patients</arm_group_label>
    <description>age: five-year-old or more
major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0
steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control patients</arm_group_label>
    <description>volunteer parents or siblings of sickle cell patients
hospital staff or their children matched on country and age +/- 3 ans with the patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood plasma saliva urines
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children and adult patients with the sickle cell disease living in subSaharan Africa
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: five-year-old or more

          -  signature of informed consent Patients : major sickle cell syndrome confirmed by
             hemoglobin phenotyping: SS, SC, SBeta+ or Sbeta0 Controls : healthy parents or
             siblings of the patients, hospital staff or their children, matched on age+/- 3 years
             and country (1 control for 4 patients)

        Exclusion Criteria:

        unstable clinical status such as:

          -  vaso-occlusive crisis in the previous 15 days

          -  fever or infectious disease in the previous 15 days

          -  transfusion in the previous 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Jouven, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiologie et Developpement</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte Ranque, MD PhD</last_name>
    <email>brigitte.ranque@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Boyer-Chatenet, MS</last_name>
    <phone>+33156093656</phone>
    <email>louise.boyer-chatenet-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Hospital of Yaounde</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Ngo Sacks, MD</last_name>
    </contact>
    <investigator>
      <last_name>Samuel Kingue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise Ngo Sacks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre mère et enfant / fondation Chantal Biya</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chelo, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Chelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anasthasie Alima, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Pasteur du Cameroun</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Belinga, MD</last_name>
    </contact>
    <investigator>
      <last_name>Suzanne Belinga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatrics unit, Centre Hospitalier d'Essos</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>guillaume Wamba, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume Wamba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Monkole</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leon Tshilolo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leon Tshilolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Unit, CHU Yopougon</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aissata Tolo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aissata Tolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kouakou Boidy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cardiologie</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIRMF</name>
      <address>
        <city>Libreville</city>
        <country>Gabon</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cardiology Unit, Centre gyneco-obstretrique</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche et de Lutte contre la Drepanocytose</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dapa Diallo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dapa Diallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim Dembele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier d'enfants Albert Royer</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahima Diagne, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ibrahima Diagne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Indou Deme-Ly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalo-universotaire de Fann, Cardiology department</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bara Diop, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bara Diop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre national de transfusion sanguine</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saliou Diop, MD</last_name>
    </contact>
    <investigator>
      <last_name>Saliou Diop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>Congo, The Democratic Republic of the</country>
    <country>Côte D'Ivoire</country>
    <country>Gabon</country>
    <country>Mali</country>
    <country>Senegal</country>
  </location_countries>
  <reference>
    <citation>Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007 Jan;21(1):37-47. Epub 2006 Nov 7. Review.</citation>
    <PMID>17084951</PMID>
  </reference>
  <reference>
    <citation>Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the &quot;hyperhemolysis paradigm&quot; for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011 Feb;86(2):123-54. doi: 10.1002/ajh.21952. Review.</citation>
    <PMID>21264896</PMID>
  </reference>
  <reference>
    <citation>Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst RJ, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Goldsmith JC, Gordeuk VR, Gladwin MT; Walk-PHASST Investigators and Patients. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013 Mar;98(3):464-72. doi: 10.3324/haematol.2012.068965. Epub 2012 Sep 14.</citation>
    <PMID>22983573</PMID>
  </reference>
  <reference>
    <citation>Gordeuk VR, Minniti CP, Nouraie M, Campbell AD, Rana SR, Luchtman-Jones L, Sable C, Dham N, Ensing G, Prchal JT, Kato GJ, Gladwin MT, Castro OL. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica. 2011 Jan;96(1):33-40. doi: 10.3324/haematol.2010.030767. Epub 2010 Sep 30.</citation>
    <PMID>20884713</PMID>
  </reference>
  <reference>
    <citation>Maier-Redelsperger M, Lévy P, Lionnet F, Stankovic K, Haymann JP, Lefèvre G, Avellino V, Perol JP, Girot R, Elion J. Strong association between a new marker of hemolysis and glomerulopathy in sickle cell anemia. Blood Cells Mol Dis. 2010 Dec 15;45(4):289-92. doi: 10.1016/j.bcmd.2010.08.001. Epub 2010 Sep 15.</citation>
    <PMID>20833087</PMID>
  </reference>
  <reference>
    <citation>Taylor JG 6th, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT, Steinberg MH. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One. 2008 May 7;3(5):e2095. doi: 10.1371/journal.pone.0002095.</citation>
    <PMID>18461136</PMID>
  </reference>
  <reference>
    <citation>Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004 Feb 26;350(9):886-95.</citation>
    <PMID>14985486</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006 Mar 15;107(6):2279-85. Epub 2005 Nov 15.</citation>
    <PMID>16291595</PMID>
  </reference>
  <reference>
    <citation>Connes P, Lamarre Y, Hardy-Dessources MD, Lemonne N, Waltz X, Mougenel D, Mukisi-Mukaza M, Lalanne-Mistrih ML, Tarer V, Tressières B, Etienne-Julan M, Romana M. Decreased hematocrit-to-viscosity ratio and increased lactate dehydrogenase level in patients with sickle cell anemia and recurrent leg ulcers. PLoS One. 2013 Nov 4;8(11):e79680. doi: 10.1371/journal.pone.0079680. eCollection 2013.</citation>
    <PMID>24223994</PMID>
  </reference>
  <reference>
    <citation>Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005 Nov 1;106(9):3264-7. Epub 2005 Jun 28.</citation>
    <PMID>15985542</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, Lehky T, Tisdale J, Gladwin MT. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol. 2006 Jul;81(7):503-10.</citation>
    <PMID>16755569</PMID>
  </reference>
  <reference>
    <citation>Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol. 2012 Aug;87(8):795-803. doi: 10.1002/ajh.23232. Epub 2012 May 28. Review.</citation>
    <PMID>22641398</PMID>
  </reference>
  <results_reference>
    <citation>Ranque B, Menet A, Boutouyrie P, Diop IB, Kingue S, Diarra M, N'Guetta R, Diallo D, Diop S, Diagne I, Sanogo I, Tolo A, Chelo D, Wamba G, Gonzalez JP, Abough'elie C, Diakite CO, Traore Y, Legueun G, Deme-Ly I, Faye BF, Seck M, Kouakou B, Kamara I, Le Jeune S, Jouven X. Arterial Stiffness Impairment in Sickle Cell Disease Associated With Chronic Vascular Complications: The Multinational African CADRE Study. Circulation. 2016 Sep 27;134(13):923-33. doi: 10.1161/CIRCULATIONAHA.115.021015. Epub 2016 Aug 31.</citation>
    <PMID>27582423</PMID>
  </results_reference>
  <results_reference>
    <citation>Ranque B, Menet A, Diop IB, Thiam MM, Diallo D, Diop S, Diagne I, Sanogo I, Kingue S, Chelo D, Wamba G, Diarra M, Anzouan JB, N'Guetta R, Diakite CO, Traore Y, Legueun G, Deme-Ly I, Belinga S, Boidy K, Kamara I, Tharaux PL, Jouven X. Early renal damage in patients with sickle cell disease in sub-Saharan Africa: a multinational, prospective, cross-sectional study. Lancet Haematol. 2014 Nov;1(2):e64-73. doi: 10.1016/S2352-3026(14)00007-6. Epub 2014 Oct 28.</citation>
    <PMID>27030156</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiologie et Développement</investigator_affiliation>
    <investigator_full_name>Xavier Jouven</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Sub-Saharan Africa</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Vasculopathy</keyword>
  <keyword>Nephropathy</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>cardiac disease</keyword>
  <keyword>hemolysis</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>blood viscosity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

